Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 0.52x is 72% below its estimated 1-year average of 1.89x, near the low end of its estimated 1-year range (0.52x–3.75x).
As of 2026-10-06T17:21:18.299Z.
Calculation as of: 2026-10-06T17:21:18.299Z.
Quote observation: 2026-10-06T17:19:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1719e487edf1987d8b1f0a43ac2cfa0d2aa61af237e007c9f807b404ec58ada8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
0.52x
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.20x
median of 521 covered companies
CURRENT VS SECTOR MEDIAN
-87.62%
vs the sector median at left
Citius Pharmaceuticals, Inc.
Market Cap
$13.56M
EV/Sales Ratio
0.52x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.51M
EV/Sales Ratio
63.82x
TTM Avg
135.82x
3Y Avg
650.44x
5Y Avg
556.96x
Market Cap
$13.69M
EV/Sales Ratio
44.83x
TTM Avg
16.53x
3Y Avg
4.93x
5Y Avg
3.45x
Market Cap
$13.76M
EV/Sales Ratio
9.58x
TTM Avg
6.53x
3Y Avg
5.18x
5Y Avg
1267.27x
Market Cap
$13.98M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.82M
EV/Sales Ratio
0.93x
TTM Avg
1.49x
3Y Avg
1.84x
5Y Avg
2.28x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $13.56M | 0.52x | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.51M | 63.82x | 135.82x | 650.44x | 556.96x |
| Vyome Holdings, Inc. (HIND)vs › | $13.69M | 44.83x | 16.53x | 4.93x | 3.45x |
| Sintx Technologies, Inc. (SINT)vs › | $13.76M | 9.58x | 6.53x | 5.18x | 1267.27x |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $13.98M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.03M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.82M | 0.93x | 1.49x | 1.84x | 2.28x |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.70M | N/A | 47034.37x | 20535.90x | 21687.86x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-10-05 | 0.53x |
| 2026-10-02 | 0.57x |
| 2026-10-01 | 0.61x |
| 2026-09-30 | 0.57x |
| 2026-09-29 | 0.66x |
| 2026-09-28 | 0.64x |
| 2026-09-25 | 0.75x |
| 2026-09-24 | 0.72x |
| 2026-09-23 | 0.71x |
| 2026-09-22 | 0.82x |
| 2026-09-21 | 0.74x |
| 2026-09-18 | 0.83x |
| 2026-09-17 | 0.78x |
| 2026-09-16 | 0.68x |
| 2026-09-15 | 0.68x |
| 2026-09-14 | 0.73x |
| 2026-09-11 | 0.76x |
| 2026-09-10 | 0.77x |
| 2026-09-09 | 0.76x |
| 2026-09-08 | 0.83x |
| 2026-09-04 | 0.78x |
| 2026-09-03 | 0.83x |
| 2026-09-02 | 0.75x |
| 2026-09-01 | 0.71x |
| 2026-08-31 | 0.75x |
| 2026-08-28 | 0.83x |
| 2026-08-27 | 0.93x |
| 2026-08-26 | 0.74x |
| 2026-08-25 | 0.84x |
| 2026-08-24 | 0.74x |
| 2026-08-21 | 0.83x |
| 2026-08-20 | 0.83x |
| 2026-08-19 | 0.96x |
| 2026-08-18 | 0.72x |
| 2026-08-17 | 0.69x |
| 2026-08-14 | 2.34x |
| 2026-08-13 | 2.25x |
| 2026-08-12 | 2.38x |
| 2026-08-11 | 2.20x |
| 2026-08-10 | 2.03x |
| 2026-08-07 | 2.05x |
| 2026-08-06 | 1.89x |
| 2026-08-05 | 2.44x |
| 2026-08-04 | 1.81x |
| 2026-08-03 | 1.70x |
| 2026-07-31 | 1.60x |
| 2026-07-30 | 1.85x |
| 2026-07-29 | 1.59x |
| 2026-07-28 | 1.31x |
| 2026-07-27 | 1.39x |
| 2026-07-24 | 1.40x |
| 2026-07-23 | 1.44x |
| 2026-07-22 | 1.57x |
| 2026-07-21 | 1.50x |
| 2026-07-20 | 1.24x |
| 2026-07-17 | 1.30x |
| 2026-07-16 | 1.36x |
| 2026-07-15 | 1.44x |
| 2026-07-14 | 1.45x |
| 2026-07-13 | 1.48x |
| 2026-07-10 | 1.65x |
| 2026-07-09 | 1.56x |
| 2026-07-08 | 1.55x |
| 2026-07-07 | 1.65x |
| 2026-07-06 | 1.75x |
| 2026-07-02 | 1.62x |
| 2026-07-01 | 1.75x |
| 2026-06-30 | 1.74x |
| 2026-06-29 | 1.63x |
| 2026-06-26 | 1.48x |
| 2026-06-25 | 1.50x |
| 2026-06-24 | 1.60x |
| 2026-06-23 | 1.56x |
| 2026-06-22 | 1.60x |
| 2026-06-18 | 1.50x |
| 2026-06-17 | 1.48x |
| 2026-06-16 | 1.49x |
| 2026-06-15 | 1.48x |
| 2026-06-12 | 1.48x |
| 2026-06-11 | 1.61x |
| 2026-06-10 | 1.53x |
| 2026-06-09 | 1.54x |
| 2026-06-08 | 1.68x |
| 2026-06-05 | 1.56x |
| 2026-06-04 | 1.68x |
| 2026-06-03 | 1.64x |
| 2026-06-02 | 1.73x |
| 2026-06-01 | 1.85x |
| 2026-05-29 | 1.94x |
| 2026-05-28 | 1.93x |
| 2026-05-27 | 2.08x |
| 2026-05-26 | 2.11x |
| 2026-05-22 | 2.12x |
| 2026-05-21 | 2.01x |
| 2026-05-20 | 1.64x |
| 2026-05-19 | 1.54x |
| 2026-05-18 | 1.43x |
| 2026-05-15 | 2.32x |
| 2026-05-14 | 2.43x |
| 2026-05-13 | 2.05x |
| 2026-05-12 | 1.85x |
| 2026-05-11 | 1.99x |
| 2026-05-08 | 1.99x |
| 2026-05-07 | 2.07x |
| 2026-05-06 | 2.14x |
| 2026-05-05 | 2.25x |
| 2026-05-04 | 2.38x |
| 2026-05-01 | 2.32x |
| 2026-04-30 | 2.30x |
| 2026-04-29 | 1.75x |
| 2026-04-28 | 2.05x |
| 2026-04-27 | 2.27x |
| 2026-04-24 | 2.70x |
| 2026-04-23 | 3.59x |
| 2026-04-22 | 3.19x |
| 2026-04-21 | 3.11x |
| 2026-04-20 | 3.27x |
| 2026-04-17 | 3.18x |
| 2026-04-16 | 3.17x |
| 2026-04-15 | 3.17x |
| 2026-04-14 | 3.00x |
| 2026-04-13 | 2.95x |
| 2026-04-10 | 2.89x |
| 2026-04-09 | 3.10x |
| 2026-04-08 | 3.03x |
| 2026-04-07 | 2.81x |
| 2026-04-06 | 3.19x |
| 2026-04-02 | 3.16x |
| 2026-04-01 | 3.10x |
| 2026-03-31 | 3.41x |
| 2026-03-30 | 2.21x |
| 2026-03-27 | 2.42x |
| 2026-03-26 | 2.29x |
| 2026-03-25 | 2.43x |
| 2026-03-24 | 2.38x |
| 2026-03-23 | 2.60x |
| 2026-03-20 | 2.71x |
| 2026-03-19 | 2.93x |
| 2026-03-18 | 3.01x |
| 2026-03-17 | 2.93x |
| 2026-03-16 | 3.31x |
| 2026-03-13 | 3.75x |
| 2026-03-12 | 3.23x |
| 2026-03-11 | 3.47x |
| 2026-03-10 | 3.58x |
| 2026-03-09 | 3.08x |
| 2026-03-06 | 3.06x |
| 2026-03-05 | 3.68x |
| 2026-03-04 | 2.96x |
| 2026-03-03 | 2.54x |
| 2026-03-02 | 2.45x |
| 2026-02-27 | 2.54x |
| 2026-02-26 | 2.62x |
| 2026-02-25 | 2.58x |
| 2026-02-24 | 2.59x |
| 2026-02-23 | 2.13x |
| 2026-02-20 | 2.37x |
| 2026-02-19 | 2.27x |
| 2026-02-18 | 2.41x |
| 2026-02-17 | 2.55x |
